Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Farmers Insurance

Generated: November 21, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,641,805

« Back to Dashboard

Summary for Patent: 5,641,805

Title: Topical ophthalmic formulations for treating allergic eye diseases
Abstract:Topical ophthalmic formulations of the invention contain as an active ingredient 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid or a pharmaceutically acceptable salt thereof. The formulations are useful for treating allergic eye diseases such as allergic conjunctivitis, vernal conjunctivitis, vernal keratoconjunctivitis, and giant papillary conjunctivitis.
Inventor(s): Hayakawa; Eiji (Susono, JP), Nakakura; Masashi (Shizuoka-ken, JP), Robertson; Stella M. (Arlington, TX), Yanni; John Michael (Burleson, TX)
Assignee: Alcon Laboratories, Inc. (Fort Worth, TX) Kyowa Hakko Kogyo Co. Ltd. (Tokyo, JP)
Application Number:08/469,729
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

No matches for this query

International Patent Family for Patent: 5,641,805

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Finland970489► Subscribe
China1161000► Subscribe
China1082367► Subscribe
Germany10299034► Subscribe
Germany69622527► Subscribe
Denmark0799044► Subscribe
European Patent Office0799044► Subscribe02C0040France► Subscribe
European Patent Office0799044► SubscribeSPC029/2002Ireland► Subscribe
European Patent Office0799044► SubscribeCA 2002 00029Denmark► Subscribe
European Patent Office0799044► SubscribeSPC/GB02/041United Kingdom► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus